NEW YORK (GenomeWeb News) — NeoGenomics and Power3 Medical Products have formed a joint venture to create a contract research organization to sell Power3’s protein biomarker-based diagnostics, NeoGenomics said today.
 
Under the agreement, NeoGenomics has non-exclusively licensed all of Power3’s intellectual property for protein biomarkers. The diagnostics the companies plan to market will be based on “one or more” of these markers, NeoGenomics said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.